By Nigel Somerville, The Deputy Sheriff of AIM | Wednesday 3 June 2015
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
As expected, Scancell Holdings (SCLP) delivered an RNS update on its ongoing Phase I/II SCIB-1 drug trials yesterday morning, following its presentation on Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The meeting itself has generated plenty of headlines, with lots of froth about a new cure for cancer from immunotherapy – the space in which Scancell operates: SCIB-1 is a treatment for melanoma. So what of the new data?
Filed under:
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Time left: 12:36:52